On Demand:
Current Treatment Strategies 2024

December 11-13 2024 - Las Vegas Nevada

“I am thankful that she told us about the latest guidelines that were updated 2 days ago.

This was a really good presentation. It made me realize I need to brush up on my CKD knowledge, especially in the setting of anemia and Bone-Mineral Density.
”
— Session 1 Comments

  • 1. Discuss the mechanisms of action, role and pros/cons of SGLT2-inhibitors and finerenone in the prevention of CKD progression.  

    2. Discuss the mechanisms of action, pharmacokinetic, and pharmacodynamic characteristics of loop and thiazide diuretic agents.

    3. Describe the mechanisms of action and pros/cons of therapies for the management of hyperkalemia, anemia, and CKD-MBD.

    4. Choose an appropriate management for edema, acute and chronic hyperkalemia, anemia, and CKD-MDB in a patient with CKD.  

    5. Discuss the mechanisms of action, role and pros/cons of current and emerging therapies for the treatment of IgA Nephropathy. 

  • Discuss the burden of opioid misuse and abuse on the individual and society.

    2. Describe the funda- mental concepts of pain management, including: a) addiction; b) tolerance; c) dependency; d) hyperalgesia; e) allodynia.

    3. State key principles for assessing patients in pain, identifying risk factors and behaviors that are associated with opioid misuse, abuse, and addiction.

    4. Describe the similarities and differences in the mechanism of action for opioids, cannabinoids and gabapentenoids.

    5. Compare and contrast the benefits, risks and role of opioids, cannabinoids and gabapentenoids in managing pain.

    6. Describe the best practice model for properly monitoring patients who are started on opioids, gabapentenoids and cannabinoids to minimize the risks of adverse reactions, over-dosage and inappropriate compliance.

    7. Compare and contrast the following product formulations of gabapentenoids with respect to their benefits and risks in managing pain: a) gabapentin (Neurontin); b) Horizant; c) Gralise; and, d) Lyrica.

    8. Compare and contrast the most common cannabinoids found in marijuana with regards to their benefits and risks in managing pain and other symptoms.

    9. State the risks of combining opioids with: a) benzodiazepines; b) alcohol; c) gabapentenoids; and d) cannabinoids.

    10. Describe how to counsel patients and caregivers regarding the safe use on naloxone for opioid overdose  

  • Protecting the Vulnerable: Improving Safety of Antimicrobials in the Elderly Population:  

    1. Evaluate methods to improve safety of antimicrobial prescribing in the elderly.  

    2. Review antimicrobial therapy recommendations within Beers Criteria.  

    3. Examine best antimicrobials practices through case application.   

    Mastering Migraine Management: Update on Current Therapies:  

    4. Review current older management strategies for migraine headaches.  

    5. Discuss role of newer agents including CGRP inhibitors.  

    6. Examine best practices through case application.  

    Obesity and Weight Loss:  

    7. Review risk factors and criteria within obesity  

    8. Describe appropriate patient populations for weight loss pharmacotherapy.  

    9. Delineate key characteristics of various approved and future pharmacotherapy options including GLP-1 and GIP agonists.  

    10. Apply knowledge within patient cases to select an appropriate pharmacotherapy option.

     

“I do see patients who are already on various pain medications including opioids and I feel much more empowered to help them navigate options and look for interactions and warning signs. ”
— Session 2 Comments
“Great program so informative and what a great approach to pain management. Lots of clinical pearls I will use. A pleasure”
— Session 3 Comments

About This Course

  • Recorded live in Las Vegas On December 11-13 2026

  • Vald through December 11-13 2027

  • Provides 15 Hours of ACPE Home Study credit.

  • Price $250

Purchase Current Treatment Strategies 2024 ON DEMAND

Learning Objectives

  • Woman smiling in a professional setting

    Dr. Sheryl (Follin) Vondracek, Pharm.D., FCCP, BCPS

    Dr. Sheryl (Follin) Vondracek, Pharm.D., FCCP, BCPS

    Board Certified Pharmacotherapy Specialist, Associate Professor, Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado

  • A group of people attending a seminar in a conference room with tables arranged in rows, a speaker presenting at the front, and a view of water outside the windows.

    Dr. Joseph Saseen, Pharm.D., FASHP, FCCP, BCPS, BCACP

    Joseph Saseen is Associate Dean for Clinical Affairs and Professor of Clinical Pharmacy and a Professor of Family Medicine. He also served as Vice Chair of the Department of Clinical Pharmacy for 10 years. Dr. Saseen has responsibilities for enhancing the school’s clinical enterprise, further developing sustainable clinical service models, and advocating for advancing the practice of pharmacy in the State of Colorado. His scholarly work includes almost 200 peer-reviewed publications and book chapters.

  • A speaker in a conference room giving a presentation on "Over-Prescribing Opioids." The slide lists reasons such as lack of training, societal medication mania, patient focus on opioids, provider confrontation phobia, and hypertrophied enabling. There is a laptop, water bottles, and electronic equipment on tables.

    Dr. Gregory L. Holmquist, PharmD, CPE

    Dr. Holmquist received his undergraduate and graduate degrees from the School of Pharmacy at the University of Washington in Seattle. He is a board certified Oncology Pharmacist, an American Medical Association Certified Educator for Physicians on Endof-Life Care, and an American Society of Pain Educators Certified Pain Educator (C.P.E.). As a clinician and educator, Dr. Holmquist’s philosophy of care is summarized in one core statement, “Making a difference in the lives of patients”

Accreditation Information - ACPE On Demand

PHARMACISTS:

  • University Learning Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. These programs are accredited for all pharmacists. On-demand courses provide HOME STUDY credit only.

  • University Learning Systems is approved by CE Broker, Tracking #50-11357 and reports to the Florida Board of Pharmacy.

  • CONSULTANT PHARMACISTS: Some consultant pharmacist boards accept University Learning Systems courses for recertification either as is or with board approval. Please contact your board regarding course approval and ULS with any questions.

  • CANADIAN PHARMACISTS:Canadian Council on Continuing Education in Pharmacy (CCCEP)accepts courses accredited by the Accreditation Council for Pharmacy Education (ACPE).  This credit is applicable to health professionals who may require pharmacology credit.

NURSE PRACTITIONERS

  • American Nurses Credentialing Center (ANCC) : This course fulfills the pharmacotherapeutics/ pharmacology requirements for American Nurses Credentialing Center (ANCC) Continuing Education Hours  or certification renewal as well as other Nurse Practitioner credentialing organizations that accept ACPE credit. The same hours submitted to renew certification may be submitted to a State Board of Nursing for re-licensure.

  • American Association of Nurse Practitioners (AANP)   This program offers Category 2 credit only. AANP only accepts on demand courses approved for  AMA PRA Category 1 Credit™. 

NURSES

  • University Learning Systems is approved by theCalifornia Board of Registered Nursing, Provider Number CEP 11409, and CE Broker Tracking #50-11357:

  • CE Broker is approved by these Boards of Nursing: Arkansas, Florida, District of Columbia, Georgia, Kentucky, New Mexico, North Dakota, South Carolina, West Virginia.The same hours submitted to renew NP certification may be submitted to a State Board of Nursing for re-licensure.

PHYSICIANS/ PHYSICIAN ASSISTANTS:

OTHER HEALTH PROFESSIONALS: Please contact your respective board regarding approval.